BASF's Evonik Gambit Tests Investor Patience Amid Ag Unit Spinoff
Published on 09/26/2026 at 09:40 | Editorial boerse-global.de
BASF shares slipped 2.6% to EUR 50.89 on Friday after the chemicals giant confirmed it is exploring a potential takeover of specialty chemicals peer Evonik, a move that has unsettled investors already digesting a sweeping corporate overhaul.
The Ludwigshafen-based group said it is in exploratory talks with RAG-Stiftung and Evonik Industries AG regarding a possible acquisition. Evonik disclosed that BASF had made an unsolicited approach concerning a voluntary public takeover offer for all of its shares, while stressing that no direct negotiations are currently underway. BASF, for its part, emphasized that both the progress and the outcome of the deliberations remain entirely open.
The news, first reported by Reuters, triggered the selloff as speculation about a major domestic acquisition collided with concerns over capital allocation. The timing is delicate: BASF is in the midst of a fundamental restructuring, and the prospect of a multi-billion-euro deal at home has raised immediate questions about how the company intends to deploy its resources.
A Spinoff Already in Motion
Just two weeks ago, BASF mandated four major banks to prepare the planned IPO of its Agricultural Solutions division, a listing targeted for completion by mid-2027. Since that announcement, the stock has shed 3.0%. The company is simultaneously pursuing several capital-intensive initiatives, including an MDI investment in India for which a subsidiary has already secured an industrial plot in Dahej, as well as partnerships such as a rapeseed marketing tie-up with Bunge. It is also separating peripheral businesses to unlock liquidity.
That balancing act—divesting on one side while weighing a major acquisition on the other—has left market participants uneasy. The central question for valuation is whether management can maintain financial discipline or whether it risks overextending itself through a large-scale project. A full takeover of an established player like Evonik would tie up capital in the double-digit billions, making the financing structure the decisive lever for the stock's trajectory. Should the deal be funded primarily through debt or a substantial capital increase, dilution or a sharp rise in leverage would loom.
Should investors sell immediately? Or is it worth buying BASF?
What a Deal Could Deliver
In an optimistic scenario, combining with Evonik would meaningfully reinforce BASF's competitive standing. Evonik holds strong positions in high-margin specialty chemicals that would complement BASF's cyclical core business. Merging the two portfolios could yield considerable synergies in procurement, logistics, and research and development, bolstering earnings power over the medium term. Consolidation in the German chemicals sector might also unlock significant savings in research, sales, and administration, while a larger share of high-margin specialty products would reduce dependence on the cyclical base chemicals business.
Some analysts remain constructive on the operational path. Bernstein Research raised its price target for BASF from EUR 62 to EUR 63 on Tuesday following discussions with management, keeping its "Outperform" rating. Proponents argue that a disciplined acquisition could sustainably strengthen BASF's position in selected core segments. If the talks collapse or are terminated early without financial burden, attention would refocus entirely on the existing cost-cutting program.
The Risks of a Costly Campaign
The bear case centers on the fear of an expensive transaction at the wrong moment. Should the unsolicited approach evolve into a formal offer for all Evonik shares, a substantial premium would likely be required, weighing heavily on the balance sheet and constraining room for future dividends or share buybacks. Integration risk compounds the concern: merging two German chemicals groups with complex production Verbund sites and regulatory requirements would absorb management capacity for years.
Because Evonik stated that no talks are currently taking place, the risk of a protracted or even hostile takeover battle remains on the table—a scenario that could durably shake investor confidence in management's strategic reliability. A megamerger would also tie up enormous managerial resources. With BASF already steering the transformation of its agricultural division, simultaneously integrating Evonik could strain operational capacity. If sentiment tips decisively toward skepticism over mounting debt, investors may have to brace for a sustained valuation discount.
Technical Support and the Next Catalyst
For now, the stock's direction hinges on signals from the boardroom. As long as the shares trade above the 200-day moving average of EUR 49.50, the long-term uptrend remains formally intact. A slide below that level would noticeably darken the technical picture and release additional selling pressure.
The next concrete catalyst is an official signal on the state of negotiations between BASF, Evonik, and RAG-Stiftung. If BASF declares the approach dead, worries about balance-sheet overstretch would likely fade quickly. If a formal offer materializes, its financing structure and the premium offered will determine the stock's fate. Clarity on both the talks and the operating situation will arrive in a few weeks: on October 28, BASF will publish its written information for the third quarter of 2026 from 7:00 a.m. Until then, every comment from the executive board on the Evonik plans is likely to set the tone for the shares, which remain in the grip of M&A speculation.
Ad
BASF Stock: New Analysis - 26 September
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
